BROSSARD, Quebec, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces a grant of an aggregate number of 1,550,000 stock options to its directors and officers. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The date of the grant is October 3, 2024. The exercise price of
BROSSARD, Quebec, Sept. 26, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the voting results of its annual general and special meeting of shareholders held on September 25, 2024. Election of directors The following directors were elected to hold office until the closing of the next annual meeting of the sharehol
BROSSARD, Quebec, Sept. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that as a result of the issuance of 8,333,333 common shares (each, a “Share”) as part of a private placement of units announced on September 20, 2024, Mr. Tristram Coffin ceased to be an insider of the Corporation since his ownership dropped below 10%. Immediately before the issuance of the Shares, Mr. Coffin ex